Allogene Therapeutics (ALLO) Assets Average (2018 - 2026)

Allogene Therapeutics has disclosed Assets Average across 9 years of filings, most recently posting $405.9 million for Q1 2026.

• Assets Average for Q1 2026 came in at $405.9 million, down 23.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $405.9 million (down 23.17% YoY), and the FY2025 annual result was $482.3 million, down 19.05% from the prior year.
• Assets Average came in at $405.9 million for Q1 2026 at Allogene Therapeutics, down from $427.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.0 billion in Q1 2022 to a low of $405.9 million in Q1 2026.
• The 5-year median for Assets Average is $618.0 million (2024), against an average of $674.0 million.
• Peak annual rise in Assets Average reached 14.03% in 2025, while the deepest fall reached 26.35% in 2025.
• Allogene Therapeutics' Assets Average stood at $858.0 million in 2022, then retreated by 20.97% to $678.1 million in 2023, then dropped by 16.1% to $568.9 million in 2024, then dropped by 24.8% to $427.8 million in 2025, then dropped by 5.12% to $405.9 million in 2026.
• The last three Assets Average figures came in at $405.9 million (Q1 2026), $427.8 million (Q4 2025), and $455.2 million (Q3 2025), per Business Quant data.